Gryphon Financial Partners’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $829K | Sell |
1,856
-39
| -2% | -$18.2K | 0.08% | 157 |
|
|
2025
Q4 | $859K | Sell |
1,895
-12
| -0.6% | -$5.17K | 0.09% | 145 |
|
|
2025
Q3 | $747K | Buy |
1,907
+784
| +70% | +$328K | 0.09% | 152 |
|
|
2025
Q2 | $500K | Buy |
1,123
+5
| +0.4% | +$2.3K | 0.07% | 182 |
|
|
2025
Q1 | $542K | Buy |
1,118
+64
| +6% | +$29.8K | 0.08% | 158 |
|
|
2024
Q4 | $424K | Sell |
1,054
-815
| -44% | -$378K | 0.06% | 170 |
|
|
2024
Q3 | $869K | Buy |
1,869
+316
| +20% | +$152K | 0.12% | 105 |
|
|
2024
Q2 | $728K | Sell |
1,553
-9
| -0.6% | -$3.91K | 0.11% | 111 |
|
|
2024
Q1 | $653K | Sell |
1,562
-416
| -21% | -$176K | 0.11% | 124 |
|
|
2023
Q4 | $486K | Buy |
1,978
+414
| +26% | +$153K | 0.09% | 152 |
|
|
2023
Q3 | $544K | Sell |
1,564
-1
| -0.1% | -$350 | 0.13% | 91 |
|
|
2023
Q2 | $551K | Buy |
1,565
+26
| +2% | +$8.76K | 0.12% | 95 |
|
|
2023
Q1 | $485K | Buy |
1,539
+6
| +0.4% | +$1.8K | 0.11% | 103 |
|
|
2022
Q4 | $443K | Sell |
1,533
-2
| -0.1% | -$610 | 0.11% | 110 |
|
|
2022
Q3 | $445K | Buy |
1,535
+17
| +1% | +$4.89K | 0.11% | 104 |
|
|
2022
Q2 | $428K | Sell |
1,518
-3
| -0.2% | -$803 | 0.1% | 113 |
|
|
2022
Q1 | $396K | Sell |
1,521
-74
| -5% | -$17.6K | 0.08% | 134 |
|
|
2021
Q4 | $350K | Sell |
1,595
-167
| -9% | -$32.5K | 0.07% | 150 |
|
|
2021
Q3 | $320K | Sell |
1,762
-178
| -9% | -$34.8K | 0.07% | 144 |
|
|
2021
Q2 | $503K | Buy |
1,940
+42
| +2% | +$8.79K | 0.11% | 92 |
|
|
2021
Q1 | $407K | Buy |
1,898
+10
| +0.5% | +$2.2K | 0.09% | 117 |
|
|
2020
Q4 | $446K | Sell |
1,888
-20
| -1% | -$4.59K | 0.11% | 98 |
|
|
2020
Q3 | $522K | Buy |
1,908
+20
| +1% | +$5.52K | 0.15% | 71 |
|
|
2020
Q2 | $548K | Sell |
1,888
-166
| -8% | -$45K | 0.17% | 61 |
|
|
2020
Q1 | $488K | Sell |
2,054
-127
| -6% | -$29.1K | 0.18% | 62 |
|
|
2019
Q4 | $478K | Buy |
2,181
+21
| +1% | +$4.25K | 0.12% | 90 |
|
|
2019
Q3 | $366K | Sell |
2,160
-5
| -0.2% | -$885 | 0.11% | 108 |
|
|
2019
Q2 | $397K | Sell |
2,165
-7
| -0.3% | -$1.22K | 0.11% | 91 |
|
|
2019
Q1 | $399K | Sell |
2,172
-8
| -0.4% | -$1.48K | 0.12% | 88 |
|
|
2018
Q4 | $361K | Sell |
2,180
-32
| -1% | -$5.54K | 0.09% | 141 |
|
|
2018
Q3 | $427K | Buy |
2,212
+1,974
| +829% | +$352K | 0.13% | 91 |
|
|
2018
Q2 | $40K | Sell |
238
-10
| -4% | -$1.55K | 0.02% | 266 |
|
|
2018
Q1 | $41K | Buy |
248
+2
| +0.8% | +$327 | 0.02% | 258 |
|
|
2017
Q4 | $37K | Buy |
+246
| New | +$36.4K | 0.02% | 303 |
|
Other funds holding VRTX
VCM
VPM
Gryphon Financial Partners's VRTX Position: Q1 2026 in Review
Gryphon Financial Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 2.1% in Q1 2026, selling an estimated $18.2K and leaving 1,856 shares worth $829K. The position accounts for 0.08% of the portfolio, ranked #157.
Gryphon Financial Partners first reported a position in VRTX in Q4 2017 and has held it in 34 quarters since. The position peaked at $869K in Q3 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Gryphon Financial Partners held 1,856 shares of Vertex Pharmaceuticals worth $829K as of Q1 2026.
- Gryphon Financial Partners sold 39 Vertex Pharmaceuticals shares in Q1 2026, an estimated $18.2K.
- Vertex Pharmaceuticals made up 0.08% of Gryphon Financial Partners's portfolio in Q1 2026, its #157 holding.
- Gryphon Financial Partners first reported a position in Vertex Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
- Gryphon Financial Partners's Vertex Pharmaceuticals position peaked at $869K in Q3 2024.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Gryphon Financial Partners's 13F filing for Q1 2026, filed 6 May 2026.